An MDCK Cell Culture-Derived Formalin-Inactivated Influenza Virus Whole-Virion Vaccine from an Influenza Virus Library Confers Cross-Protective Immunity by Intranasal Administration in Mice

Haredy, Ahmad M.; Takenaka, Nobuyuki; Yamada, Hiroshi; Sakoda, Yoshihiro; Okamatsu, Masatoshi; Yamamoto, Naoki; Ômasa, Takeshi; Ohtake, Hisao; Mori, Yasuko; Kida, Hiroshi; Yamanishi, Koichi; Okamoto, Shigefumi

doi:10.1128/cvi.00024-13

Cited by 12 publications

(15 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The immunogenicity and protective effect of WVP were compared with those of SV in MN vaccination in mice to determine a suitable vaccine formulation for MN. [23,24], were used in the present study. All viruses were propagated in 10-day-old embryonated chicken eggs at 35°C for 36-48 h, and the infectious allantoic fluids were collected.…”

Section: Introductionmentioning

confidence: 99%

Potency of whole virus particle and split virion vaccines using dissolving microneedle against challenges of H1N1 and H5N1 influenza viruses in mice

Nakatsukasa

Kuruma

Okamatsu

et al. 2017

Vaccine

Self Cite

View full text Add to dashboard Cite

Transdermal vaccination using a microneedle (MN) confers enhanced immunity compared with subcutaneous (SC) vaccination. Here we developed a novel dissolving MN patch for the influenza vaccine. The potencies of split virion and whole virus particle (WVP) vaccines prepared from A/Puerto Rico/8/1934 (H1N1) and A/duck/Hokkaido/Vac-3/2007 (H5N1), respectively, were evaluated. MN vaccination induced higher neutralizing antibody responses than SC vaccination in mice. Moreover, MN vaccination with a lower dose of antigens conferred protective immunity against lethal challenges of influenza viruses than SC vaccination in mice. These results suggest that the WVP vaccines administered using MN are an effective combination for influenza vaccine to be further validated in humans.

show abstract

Section: Introductionmentioning

confidence: 99%

Potency of whole virus particle and split virion vaccines using dissolving microneedle against challenges of H1N1 and H5N1 influenza viruses in mice

Nakatsukasa

Kuruma

Okamatsu

et al. 2017

Vaccine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mouse adaptation of viruses. To generate the challenge strains for protection experiments, A/duck/Hokkaido/77 (H3N2) and A/Aichi/2/ 68 (H3N2) strains that were pathogenic in mice were generated as described in our previous report (Haredy et al, 2013). Briefly, mice were intranasally infected with virus (10 8 p.f.u.…”

Section: Methodsmentioning

confidence: 99%

“…Influenza vaccines. The seed viruses H3N2, H3N4, H3N5 and H3N7 were grown for vaccine production using the BelloCell cell culture system (CESCO Bioengineering), and the WV vaccines after formalin inactivation were prepared as described previously (Haredy et al, 2013). The vaccine concentrations were adjusted to 1, 0.1 or 0.01 mg per 20 ml dose.…”

Section: Methodsmentioning

confidence: 99%

Neuraminidase gene homology contributes to the protective activity of influenza vaccines prepared from the influenza virus library

Haredy

Yamada

Sakoda

et al. 2014

Journal of General Virology

Self Cite

View full text Add to dashboard Cite

Whole-virus (WV) vaccines from influenza A/duck/Hokkaido/77 (H3N2), and its reassortant strains H3N4, H3N5 and H3N7, which have the same haemagglutinin (HA) gene but different neuraminidase (NA) genes, were prepared from our influenza virus library. Mice were intranasally immunized with equivalent doses of each vaccine (1-0.01 mg per mouse). All of the mice that received the highest dose of each vaccine (1 mg per mouse) showed equivalent high HAinhibiting (HI) antibody titres and survived the H3N2 challenge viruses. However, mice that received lower doses of vaccine (0.1 or 0.01 mg per mouse) containing a heterologous NA had lower survival rates than those given the H3N2-based vaccine. The lungs of mice challenged with H3N2 virus showed a significantly higher virus clearance rate when the vaccine contained the homologous NA (N2) versus a heterologous NA, suggesting that NA contributed to the protection, especially when the HI antibody level was low. These results suggested that, even if vaccines prepared for a possible upcoming pandemic do not induce sufficient HI antibodies, WV vaccines can still be effective through other matched proteins such as NA.

show abstract

“…Publications from China and India, where many new vaccine processes are currently established, show vaccine producers clearly prefer established cells such as Vero and MDCK to obtain licensure more quickly [16, 17]. To the author's knowledge, there are currently no examples of licensed vaccines produced with the so‐called new designer cells (PER.C6, CAP, EB66 or AGE1.CR).…”

Section: What Are “Designer Cells”?mentioning

confidence: 99%

Designing cell lines for viral vaccine production: Where do we stand?

Genzel

2015

Biotechnology Journal

101

View full text Add to dashboard Cite

Established animal cells, such as Vero, Madin Darby canine kidney (MDCK) or chicken embryo fibroblasts (CEFs), are still the main cell lines used for viral vaccine production, although new "designer cells" have been available for some years. These designer cell lines were specifically developed as a cell substrate for one application and are well characterized. Later screening for other possible applications widened the product range. These cells grow in suspension in chemically defined media under controlled conditions and can be used for up to 100 passages. Scale-up is easier and current process options allow cultivation in disposable bioreactors at cell concentrations higher than 1 × 10(7) cells/mL. This review covers the limitations of established cell lines and discusses the requirements and screening options for new host cells. Currently available designer cells for viral vaccine production (PER.C6, CAP, AGE1.CR, EB66 cells), together with other new cell lines (PBS-1, QOR/2E11, SogE, MFF-8C1 cells) that were recently described as possible cell substrates are presented. Using current process knowledge and cell line development tools, future upstream processing could resemble today's Chinese hamster ovary (CHO) cell processes for monoclonal antibody production: small scale bioreactors (disposable) in perfusion or fed-batch mode with cell concentrations above 1 × 10(8) cells/mL.

show abstract

An MDCK Cell Culture-Derived Formalin-Inactivated Influenza Virus Whole-Virion Vaccine from an Influenza Virus Library Confers Cross-Protective Immunity by Intranasal Administration in Mice

Cited by 12 publications

References 44 publications

Potency of whole virus particle and split virion vaccines using dissolving microneedle against challenges of H1N1 and H5N1 influenza viruses in mice

Potency of whole virus particle and split virion vaccines using dissolving microneedle against challenges of H1N1 and H5N1 influenza viruses in mice

Neuraminidase gene homology contributes to the protective activity of influenza vaccines prepared from the influenza virus library

Designing cell lines for viral vaccine production: Where do we stand?

Contact Info

Product

Resources

About